If you think depression
only affects the individual suffering from the disorder, or even their friends
and family, think again. As a nation, depression affects all of us in one way
or another. According to a report from the Journal of Clinical Psychology, a
staggering amount of that impact is economic.
Depression (MDD) is the
leading cause of disability for people aged 15-44, reports OptumHealth
Reporting and Insights. Financially, that equates to billions of dollars spent
on workplace costs, direct costs (which includes medical claims and
pharmaceuticals) and suicide-related costs. Annual costs of MDD rose 21% to
$210.5 billion in 2010, according to the Journal of Clinical Psychology,
compared to costs in 2005.
Most experts agree that
depression rates worldwide are on the rise. While there are nearly 50
variations of anti-depressants available in the U.S. alone, the often extensive
trial and error process of finding a drug combination that reduces a patient’s
depression symptoms is known to take months, even more than a year, and
involves risks of serious side effects, including suicide. Studies show that
fewer than 40% of depression sufferers benefit from first round treatments with
current antidepressants, and the likelihood of achieving remission of depressive
symptoms declines with each successive treatment attempt. Even more atrocious,
as many as 15% of individuals suffering with MDD commit suicide.
There is an obvious,
unarguable need for a breakthrough – a new generation of safe and faster-acting
antidepressants.
One such candidate is
ketamine, often used as an anesthetic but also popular as a dangerous street
drug. The risk of potential abuse of ketamine, its intravenous administration,
and its psychosis-like side effects somewhat crimp widespread acceptance in the
medical field. And yet, ketamine’s rapid-acting effectiveness against
treatment-resistant MDD is hard to ignore.
In San Francisco, a
publicly traded, clinical-stage biopharmaceutical company is hard at work
advancing its equally, if not more promising, solution – AV-101, an orally
active NMDA receptor modulator.
Backed with funding by the
U.S. National Institutes Health (NIH), VistaGen Therapeutics is collaborating
with Dr. Carlos Zarate – a highly esteemed NIH clinician known for his deep
experience with ketamine and other NMDA receptor antagonists – on a phase 2
clinical study of the efficacy and safety of AV-101 in subjects with MDD. As
reflected by the NIH’s support, VistaGen’s AV-101 has the potential to deliver
the rapid-acting antidepressant effects of ketamine, but without any of
ketamine’s serious side effects.
Dr. Carlos Zarate is among
the NIH’s leading clinical researchers on depression and other mood disorders,
serving as the Chief of the Section on the Neurobiology and Treatment of Mood
Disorders and Chief of the Experimental Therapeutics and Pathophysiology Branch
at the National Institutes of Mental Health (NIMH). He will be the principal
investigator of the NIH-funded Phase 2 study of AV-101 in MDD. VistaGen and the
NIH anticipate completing this important study in 2015.
In two prior NIH-funded
randomized, double-blind, placebo-controlled phase 1 safety studies, AV-101 was
well-tolerated and not associated with any severe adverse events. Nor were
there any signs of sedation, hallucinations or schizophrenia-like side effects
often associated with ketamine.
In addition to its
candidacy as an effective MDD treatment, preclinical studies have also shown
AV-101 as a potential as a treatment for other widespread CNS-related conditions,
including chronic neuropathic pain and epilepsy, Parkinson’s and Huntington’s
disease.
For more information,
visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment